Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06730100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Withdrawn
Start date
February 17, 2026
Completion date
December 1, 2026
Enrollment
0 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic mismatch repair proficient colorectal carcinoma, refractory mismatch repair proficient colorectal carcinoma, stage iv colorectal cancer ajcc v8